학술논문

Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2.
Document Type
Article
Source
Oncologist; Jul2019, Vol. 24 Issue 7, p893-900, 8p, 1 Diagram, 1 Chart, 3 Graphs
Subject
BREAST cancer prognosis
EXEMESTANE
EVEROLIMUS
BREAST tumors
CELL receptors
COMBINATION drug therapy
CONFIDENCE intervals
GENE expression
METASTASIS
MULTIVARIATE analysis
TUMOR markers
TUMOR classification
RANDOMIZED controlled trials
PROPORTIONAL hazards models
RETROSPECTIVE studies
ODDS ratio
THERAPEUTICS
GENETICS
Language
ISSN
10837159
Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)